The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625.
Isabel Blancas
No relevant relationships to disclose
Manuel Ruiz-Borrego
No relevant relationships to disclose
Javier Salvador Bofill
No relevant relationships to disclose
Veronica Conde
No relevant relationships to disclose
Francisco Carabantes
No relevant relationships to disclose
Juan L. Bayo
No relevant relationships to disclose
Ana Jaen
No relevant relationships to disclose
Elisabeth Perez Ruiz
No relevant relationships to disclose
MarĂ­a del Mar Santiago
No relevant relationships to disclose
Jose Manuel Baena
No relevant relationships to disclose
Vicente Villareal
No relevant relationships to disclose
Antonia Martinez Guisado
No relevant relationships to disclose
Luis de la Cruz Merino
No relevant relationships to disclose
Pedro Rodriguez
No relevant relationships to disclose
Evelyn Reyes
Employment or Leadership Position - AstraZeneca
Rosana Cajal
Employment or Leadership Position - AstraZeneca
Mayte Delgado
No relevant relationships to disclose
Encarnacion Gonzalez Flores
No relevant relationships to disclose
Angel Inoriza
No relevant relationships to disclose
Pedro Sanchez Rovira
No relevant relationships to disclose